A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
Condition: Endometriosis · Sponsor: Kissei Pharmaceutical Co., Ltd.
About this study
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe endometriosis-associated pain (EAP).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (112)
| Birmingham OBGYN / ID # 740 | Birmingham, Alabama, United States | — |
| Mesa Obstetricians and Gyneocologists / ID # 790 | Mesa, Arizona, United States | — |
| Precision Trials AZ, LLC / ID # 783 | Phoenix, Arizona, United States | — |
| Quality of LIfe Medical & Research Center, LLC / ID # 813 | Tucson, Arizona, United States | — |
| Visions Clinical Research-Tucson / ID # 754 | Tucson, Arizona, United States | — |
| Lynn Institute of the Ozarks / ID # 826 | Little Rock, Arkansas, United States | — |
| Applied Research Center of Arkansas / ID # 735 | Little Rock, Arkansas, United States | — |
| Join Clinical Trials / ID # 778 | Huntington Park, California, United States | — |
| Long Beach Clinical Trials, LLC / ID # 768 | Long Beach, California, United States | — |
| Matrix Clinical Research / ID # 751 | Los Angeles, California, United States | — |
| Futura Research, Org / ID # 781 | Norwalk, California, United States | — |
| National Research Institute / ID # 805 | Panorama City, California, United States | — |
+ 100 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03986944